US NIAID cancels novel HIV vaccine trial
This article was originally published in Scrip
Executive Summary
The protracted search for an effective vaccine to prevent HIV has been dealt another blow after the US National Institute of Allergy and Infectious Diseases (NIAID), part of theNIH, decided not to conduct a large Phase IIb study with its potentially promising candidate, although a smaller study is being considered.